Teriparatide
Muscle/RecoveryFDA-approved PTH(1-34)Established
FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk. 20 mcg SC daily; cumulative use generally ≤2 years.
For research use only.
Key Facts
- CAS
- 52232-67-4
- Molecular Weight (MW)
- 4117.8 g/mol
- Half-life
- ~1 hour (sc)
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- 8/23/2026
- Targets
- PTH1 receptor
Overview
FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk. 20 mcg SC daily; cumulative use generally ≤2 years.
Protocol
- Dosage Range
- 20 mcg daily
- Frequency
- Once daily
- Cycle
- Maximum 2 years of treatment
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Prefilled pen - no reconstitution needed
Science
Mechanism of Action
Intermittent PTH1R activation increases osteoblast number and bone formation, reducing vertebral and nonvertebral fractures.
Targets
PTH1 receptor
Studies
- Neer teriparatide fracture trial— Journal/year not available
Benefits
Anabolic osteoporosis therapy
Potential Side Effects
- Hypercalcemia
- Nausea
- Leg cramps
- Orthostasis
References
- FDA label — ForteoExternal link · Year —